Hengrui Pharmaceutical (600276.SH): Received a complete response letter on injectable carelizumab
On May 17, Ge Longhui Pharmaceutical (600276.SH) announced that it has received a complete response letter from the US Food and Drug Administration (“FDA”) regarding the biological product license application for injectable carelizumab combined with apatinib mesylate tablets for first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma. In the response letter, the FDA stated that it would conduct a comprehensive assessment based on the company's complete response to inspection defects at the production site; and due to travel restrictions in some countries, the FDA stated that it was not possible to complete all of the biological research monitoring program (BIMO) clinical examinations required for the project during the review period
Hong Kong Stock Concept Tracking | Hengrui Pharmaceutical's GLP-1 Products Achieve Active Layout for Foreign Authorized Domestic and Foreign Companies (with Concept Shares)
The wave of research and development of GLP-1 drugs continues to heat up as market demand increases and the development of new drugs advances
Hengrui diet pills went overseas for 6 billion US dollars, and this time they are no longer making wedding gowns for others | Insight Research
Through an innovative transaction structure, Hengrui uses minimal risk to obtain the highest potential overseas returns, while providing shareholders with more stable returns.
Hengrui Pharmaceutical (600276.SH): Plans to license the GLP-1 product portfolio to Hercules of the United States for a fee
GLONGHUI May 16 丨 Hengrui Pharmaceutical (600276.SH) announced that the company will license the GLP-1 product portfolio with independent intellectual property rights to Hercules of the United States for a fee, and Hercules of the United States will obtain the exclusive right to develop, produce and commercialize the GLP-1 product portfolio on a global scale other than Greater China. As part of the consideration for the foreign licensing transaction, Hengrui will acquire 19.9% of the shares in Hercules of the United States and will obtain licensing fees for the GLP-1 product portfolio from Hercules of the United States. GLP-1 product portfolio
Hengrui Pharmaceuticals Plans Up to 1.2 Billion Yuan Share Buyback
Jiangsu Hengrui Pharmaceuticals (SHA:600276) plans to spend between 600 million yuan and 1.2 billion yuan to buy back shares, according to a filing with the Shanghai Stock Exchange. The repurchased sh
Gelonghui Announcements Selected | Changqing Technology: Plans to invest 10 billion yuan to build a new polymer material production base, with an annual production capacity of 80,000 tons of paraphthalic anhydride, etc.; Nanjing Chemical Fiber: The main b
[Hot Focus] Nanjing Chemical Fiber (600889.SH): The main business is still cellulose fiber and PET structural core material Nanjing Chemical Fiber (600889.SH) announced abnormal stock price fluctuations. Currently, the company's main business is still cellulose fiber and PET structural core materials. The company's production and operation situation is normal, and there have been no major changes. The company has no material matters that should have been disclosed but not disclosed. Onli Education (600661.SH): With education and training as its main business, the daily business conditions are normal Onli Education (600661.SH) announced an announcement on abnormal stock trading fluctuations. The company's 2023
Hengrui Pharmaceutical (600276.SH): A total cost of 635 million yuan to buy back 0.22% of the shares
Gelonghui, May 15, 丨 Hengrui Pharmaceutical (600276.SH) announced that on May 14, 2024, the company's share repurchase period expired. The actual share repurchase was 14,351,878 shares, accounting for 0.22% of the company's total share capital. The highest transaction price was 47.01 yuan/share, and the minimum transaction price was 41.09 yuan/share. The average repurchase price was about 44.22 yuan/share, and the total transaction amount was 634,665,849.66 yuan (excluding transaction fees).
Hengrui Pharmaceuticals Unit Gets China Clinical Trial Approval for Kidney Medication
China's medical products administrator approved Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Guangdong Hengrui Pharmaceutical's clinical trial for its SHR-2173 injection, according to a Wednesday
Hengrui Pharmaceutical (600276.SH): SHR-2173 injection obtained drug clinical trial approval notice
Gelonghui May 14 丨 Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Guangdong Hengrui Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for SHR-2173 injections and will conduct clinical trials in the near future. SHR-2173 injection is a therapeutic biological product independently developed by the company. It can exert anti-inflammatory and immune-suppressing biological effects by targeting abnormally activated immune cells. It is expected to reduce autoantibody levels, improve the disease activity status of patients with IgA nephropathy, and bring new treatment options to patients. Currently none at home or abroad
Hehuang Pharmaceutical (00013.HK) and Hengrui Pharmaceutical reached a cooperation and initiated a phase II/III study on surufatinib (surufatinib) combined with camrelizumab (camrelizumab) in the treatment of primary pancreatic ductal adenocarcinoma
Gelonghui, May 14, 丨 Hehuang Pharmaceutical (00013.HK) announced the launch of a Chinese phase II/III clinical trial today to evaluate Hehuang Pharmaceutical's drug candidate surufatinib (surufatinib), the PD-1 antibody camrelizumab (camrelizumab) of Jiangsu Hengrui Pharmaceutical Co., Ltd. (“Hengrui Pharmaceutical”), albumin-conjugated paclitaxel (nab-paclitaxel), and gemcitabine (gemcitabine) for first-line treatment of metastatic pancreatic conduction Ductal adenocarcinoma (PDAC) patients
Hengrui Pharma's Unit Gets Regulatory Nod to Trial HRS-5965 Capsules
China's National Medical Products Administration approved Jiangsu Hengrui Pharmaceuticals' (SHA:600276) unit, Chengdu Shengdi Pharmaceutical's application to conduct clinical trials on HRS-5965 capsul
Illustration丨Capital from North China bucked the trend and added positions to Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare
The net sale of A-shares today was 4,044 billion yuan, the second consecutive day of net sales. Among them, Ping An Bank, Guodian Nanrui, and Zhongji Xuchuang received net sales of 255 million yuan, 242 million yuan, and 204 million yuan respectively; Huichuan Technology, Hengrui Pharmaceutical, and Mindray Healthcare bucked the trend and received net purchases of 395 million yuan, 299 million yuan, and 221 million yuan respectively. According to statistics, the capital from North China has been increasing Kweichow Moutai for 3 consecutive days, for a total of 4.265 billion yuan.
Hengrui Pharmaceutical (600276.SH): HRS5580 for injection was approved for clinical trials to prevent nausea and vomiting after surgery
Hengrui Pharmaceutical (600276.SH) announced that recently, the company's subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the national drug...
Hengrui Pharmaceutical (600276.SH): HRS-5965 capsules obtained drug clinical trial approval notice
Gelonghui May 8 丨 Hengrui Pharmaceutical (600276.SH) announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. has received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-5965 capsules and will conduct clinical trials in the near future. HRS-5965 capsules can inhibit complement system-mediated hemolysis by inhibiting excessive activation of the complement system. Preclinical studies showed that it had a significant inhibitory effect in complement-mediated hemolysis models and was safe.
Hengrui Pharmaceutical (600276.SH): cumulative repurchase of 0.22% of shares
Gelonghui, May 6, 丨 Hengrui Pharmaceutical (600276.SH) announced that as of April 30, 2024, the company had repurchased a total of 14,351,878 shares through centralized bidding transactions, accounting for 0.22% of the company's total share capital. The highest transaction price was 47.01 yuan/share, the lowest price was 41.09 yuan/share, and the total amount paid was 634,665,849.66 yuan (excluding transaction fees).
Hengrui Pharmaceutical (600276.SH) launches phase III study on long-acting insulin+GLP-1 analogue compound formulation
On April 28, the drug clinical trial registration and information disclosure platform showed that Hengrui Pharmaceutical (600276.SH) initiated a phase III clinical trial (CTR20241529) of HR17031 injections with randomized, open, parallel control, and treatment compliance.
Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3%
Jiangsu Hengrui Pharmaceuticals (SHA:600276) will conduct clinical trials on insulin aspart injection after receiving approval from China's National Medical Products Administration, according to the c
Why Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Are Better Than They Seem
Despite posting healthy earnings, Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276 ) stock has been quite weak. We have done some analysis, and found some encouraging factors that we believe the sha
Haitong International: Free circuit with long slopes and heavy snow, domestic market space is expected to open up
The Zhitong Finance App learned that Haitong International released a research report saying that compared with innovative domestic drugs to replace relatively mature oncology drugs, self-exempt drugs also have the advantage of a large market size (suitable for the domestic pricing environment for new drugs). The differences are that patients are widely distributed (channel coverage is required), are more chronic diseases, and there is competition for traditional drugs (requiring fast efficacy and high accessibility). Combined with the current market financing environment, although the self-defense target layout is still crowded, companies with good cash flow will be more likely to obtain excess profits. It is recommended to pay attention to Hengrui Pharmaceutical (600276.SH), Kangzhe Pharmaceutical (00867), Sansheng Guojian (688)
Hengrui Pharmaceutical's 2023 performance rebounded steadily, and the sales expense ratio declined year-on-year
On the evening of April 17, Hengrui Pharmaceutical released its 2023 annual report. In 2023, Hengrui Pharmaceutical achieved operating income of 22.82 billion yuan, up 7.26% year on year, net profit attributable to shareholders of listed companies of 4.302 billion yuan, up 10.14% year on year, deducted non-net profit attributable to shareholders of listed companies of 4.141 billion yuan, up 21.46% year on year, net operating cash flow of 7.644 billion yuan, a sharp increase of 504.12% year on year. According to the report's analysis, as Hengrui Pharmaceutical's innovative achievements continue to be approved, the clinical value of innovative drugs is highlighted, driving revenue growth. 2023
No Data